CIK 0001737287
- Non-accelerated filer
- Smaller reporting company
Allogene Therapeutics, Inc.
Sign in to watch- Ticker
- ALLO
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Entity type
- Operating
- EIN
- 823562771
- Phone
- +1 650-457-2700
- Business address
- 210 EAST GRAND AVENUE, SOUTH SAN FRANCISCO, CA, 94080
- 4 Grant or award CHIEF FINANCIAL OFFICER acquired 790,000 shares (grant or award)
- 3 Insider Initial Statement of Ownership
- 4 Grant or award GENERAL COUNSEL acquired 435,834 shares (grant or award)
- 3 Insider Initial Statement of Ownership
- 4 Grant or award SVP, Finance acquired 11,401 shares (grant or award)
- 3 Insider Initial Statement of Ownership
- 4 Open-market sale Director sold 10,000 shares at $4.29 ($42,855)
- 4 Grant or award Director acquired 74,561 shares (grant or award)
- 4 Derivatives Options or other derivatives
- 4 Grant or award Director acquired 59,649 shares (grant or award)
- 4 Grant or award Director acquired 74,561 shares (grant or award)
- 4 Grant or award Director acquired 74,561 shares (grant or award)
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Grant or award Chief Technical Officer acquired 186,219 shares (grant or award)
- 3 Insider Initial Statement of Ownership
- 4 Grant or award VP, Corporate Counsel acquired 56,545 shares (grant or award)
- 3 Insider Initial Statement of Ownership
- 4 Grant or award Chief Technical Officer acquired 558,094 shares (grant or award)
- 4 Grant or award Chief Financial Officer acquired 558,094 shares (grant or award)
Page 5 of 14 · 275 filings